Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T20:38:32.440Z.
Calculation as of: 2026-10-06T20:38:32.440Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e8daa83f2db5fafa0746e2d75675d68491b64c400a2027f88c30977eae97731f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$344.04M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$349.70M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$353.88M
Price/FCF Ratio
N/A
TTM Avg
54.19
3Y Avg
39.66
5Y Avg
37.45
Market Cap
$355.36M
Price/FCF Ratio
12.15
TTM Avg
32.60
3Y Avg
51.28
5Y Avg
207.97
Market Cap
$355.43M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$359.53M
Price/FCF Ratio
N/A
TTM Avg
6.69
3Y Avg
6.69
5Y Avg
6.69
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Turn Therapeutics Inc. (TTRX) | $346.73M | N/A | N/A | N/A | N/A |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.04M | N/A | N/A | N/A | N/A |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.70M | N/A | N/A | N/A | N/A |
| Ocugen, Inc. (OCGN)vs › | $352.67M | N/A | N/A | N/A | N/A |
| Embecta Corp. (EMBC)vs › | $353.00M | 2.14 | 2.83 | 26.37 | 19.21 |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.88M | N/A | 54.19 | 39.66 | 37.45 |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 12.15 | 32.60 | 51.28 | 207.97 |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | N/A | N/A | N/A | N/A |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.53M | N/A | 6.69 | 6.69 | 6.69 |
| Opus Genetics, Inc. (IRD)vs › | $361.64M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
